ENTITY
BeiGene

BeiGene (6160 HK)

309
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
12 Nov 2018 09:54

Junshi Bioscience (君实医药) IPO: Early in Application but Behind in Key Indications (Part 1)

Shanghai Junshi Biosciences, a China-based biotechnology company listed on the NEEQ market (ticker 833330.NEEQ) with a market capitalization of USD...

Logo
477 Views
Share
bearishSoftbank Group
12 Nov 2018 06:05

Last Week in GER Research: Softbank, Haidilao, Tongcheng-Elong, Ctrip and 360 Finance

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team.  This week we update on Softbank Group (9984...

Logo
338 Views
Share
bearishSoftbank Group
05 Nov 2018 06:03

Last Week in GER Research: Softbank, Babytree, Tencent Music, MYOB, Yancoal, Spotify Warning & More!

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team.  Last week, Arun initiated IPO coverage...

Logo
310 Views
Share
01 Nov 2018 14:21

Innovent Biologics (信达生物) Post IPO: Hit Our TP, What's Next?

Innovent Biologics was priced at the high end and it started trading yesterday (November 1st). It traded up by 18.5% on the first day and 8% on the...

Logo
541 Views
Share
31 Oct 2018 16:39

Innovent Biologics IPO First-Day: Take Money off the Table

Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...

Logo
521 Views
Share
x